Mirikizumab is one of a slate of anticipated drug launches Lilly is relying on to add billions more to its yearly sales totals.
Others include the fast-selling diabetes drug Mounjaro — which could soon be cleared as a weight-loss treatment — as well as the Alzheimer’s medicine donanemab and the eczema treatment lebrikizumab. In January, its cancer drug Jaypirca was approved for mantle cell lymphoma.
